These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 9128388

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.
    Inglis HR, Csurhes PA, McCombe PA.
    J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):419-22. PubMed ID: 17158557
    [Abstract] [Full Text] [Related]

  • 67. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders.
    Goldschmidt B, Menonna J, Fortunato J, Dowling P, Cook S.
    Ann Neurol; 1980 Feb; 7(2):108-12. PubMed ID: 7369715
    [Abstract] [Full Text] [Related]

  • 68. Concurrent acute disseminated encephalomyelitis and Guillain-Barré syndrome in a child.
    Deshmukh IS, Bang AB, Jain MA, Vilhekar KY.
    J Pediatr Neurosci; 2015 Feb; 10(1):61-3. PubMed ID: 25878749
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Immune reactions to P2 protein in human inflammatory demyelinative neuropathies.
    Zweiman B, Rostami A, Lisak RP, Moskovitz AR, Pleasure DE.
    Neurology; 1983 Feb; 33(2):234-7. PubMed ID: 6600513
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. [Acute polyradiculoneuropathy of Guillain-Barré. Critical review of potential etiopathogeneses].
    Guadagnino M, Petitto F.
    Riv Neurol; 1985 Feb; 55(6):402-23. PubMed ID: 3008302
    [Abstract] [Full Text] [Related]

  • 75. Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?
    Zhang HL, Wu L, Wu X, Zhu J.
    Expert Opin Ther Targets; 2014 Apr; 18(4):355-63. PubMed ID: 24479493
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Autonomic involvement in Guillain-Barré syndrome: a review.
    Zochodne DW.
    Muscle Nerve; 1994 Oct; 17(10):1145-55. PubMed ID: 7935521
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.